Please assess the completion status of the following clinical trial:

Trial Title: Use of Labeled Glucose to Study Lymphocyte Replication and Survival in HIV-Infected Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~FOR PATIENTS:~18 years or older.~Able to provide informed consent and willing to comply with study requirements and clinic policies.~Negative urine pregnancy test (for women of childbearing potential).~Hemoglobin greater than 10 mg/dl.~Adequate venous access in the arms for blood drawing and 5 day infusions, and lymphapheresis~Willingness to allow stored samples to be used for future studies of HIV infection and/or immunological function, and willingness to have HLA typing performed. (For previously enrolled patients, patients would be requested, but not required, to provide permission to use stored samples in the future, and to permit HLA testing~FOR HIV POSITIVE PATIENTS:~Documented HIV infection (ELISA/Western blot positive or, for acute seroconverters, PCR positive).~FOR HIV NEGATIVE PATIENTS:~Negative ELISA/Western blot.~EXCLUSION CRITERIA:~Diabetes mellitus requiring drug therapy.~Active substance abuse or prior history of substance abuse which may interfere with protocol compliance.~Psychiatric illness or disturbance which, in the assessment of the protocol team, may affect patient safety or compliance.~Significant underlying cardiac, pulmonary, renal, gastrointestinal, rheumatologic or CNS disease as detectable on routine history, physical exam, or screening laboratory studies. Patients would be excluded if they had an acute or chronic underlying medical problem that in the judgment of the principal investigator could be exacerbated by participating in the protocol or that would make it difficult for them to comply with the protocol requirements.~Pregnancy or breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- HIV-infected subjects (Type: EXPERIMENTAL): HIV-infected adults
- HIV-negative subjects (Type: EXPERIMENTAL): HIV-negative adults

Based on this trial design, predict the completion outcome and termination type (if applicable).